Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01617213 · ClinicalTrials.gov registry record · Phase 2
Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma
A Phase 2 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01617213: Clinical Trial Phase 2 study, sponsored by University of Virginia.
NCT01617213 is a Phase 2 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01617213, a Phase 2 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.
Primary Outcome
Duration of time until patient experiences an event (recurrence, relapse or death)
Interventions
- DRUG Melphalan
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-04 |
| Phase | Phase 2 |
Why NCT01617213 stopped before completion
NCT01617213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Melphalan is the first listed.
NCT01617213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01617213 about?
NCT01617213 is a clinical study titled "Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma". This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.
What is the current status of trial NCT01617213?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2012-04.
What interventions are being tested in trial NCT01617213?
The interventions under investigation include: Melphalan (DRUG), Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01617213?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01617213's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia